European Notebook: EMA Meetings Go (Somewhat) Public; Walgreens’ Global Reach; Scottish Independence?
The European Medicines Agency moves closer to U.S.-style advisory committee meetings in public; two national referendums next month could hit Scotland’s biotech industry and Switzerland’s health insurance sector.
You may also be interested in...
Roche paying $450 million for Danish biotech Santaris is likely to fuel excitement around RNA-targeting technologies and may generate a liquidity boost for Europe’s VC sector.
Walgreens is acquiring 45% of the U.K.-based international retailer and wholesaler Alliance Boots, which runs pharmacies in 11 countries, with an option to acquire the entire firm in three years.
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.